BMJ Learning : Benign prostatic hyperplasia: treatment in primary care
- 7 September 2006
- Vol. 333 (7567), 535-539
- https://doi.org/10.1136/bmj.38946.616551.be1
Abstract
This article provides information on how to treat patients with lower urinary tract symptoms that are suggestive of bladder outflow obstruction, secondary to benign prostatic hyperplasiaThis publication has 18 references indexed in Scilit:
- Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profileBJU International, 2005
- Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α1‐adrenoceptor antagonistsBJU International, 2005
- Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual functionBJU International, 2005
- Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular systemBJU International, 2005
- EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines)European Urology, 2004
- INTERACTION BETWEEN THE PHOSPHODIESTERASE 5 INHIBITOR, TADALAFIL AND 2 α-BLOCKERS, DOXAZOSIN AND TAMSULOSIN IN HEALTHY NORMOTENSIVE MENJournal of Urology, 2004
- Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinicianBJU International, 2004
- Guideline for the primary care management of male lower urinary tract symptomsBJU International, 2004
- Safety and Tolerability of the Dual 5α-Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic HyperplasiaEuropean Urology, 2003
- Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension StudyEuropean Urology, 2002